Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Camrelizumab plus neoadjuvant chemotherapy and concurrent chemoradiotherapy for locally advanced cervical cancer
ChiCTR2500101118Phase 2Not yet recruiting
- Sponsor
- Lu'an Hospital of Anhui Medical University
- Start
- Apr 2025
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of camrelizumab, paclitaxel and carboplatin in Cervical Cancer (CC), sponsored by Lu'an Hospital of Anhui Medical University. Primary endpoint: 2-year progression-free survival rate. Planned start Apr 2025; status: not yet recruiting.
02
Drugs
camrelizumabpaclitaxelcarboplatin
03
Conditions
Cervical Cancer (CC)
Beyond the preview
Go deeper on ChiCTR2500101118.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500101118.